Published in TB and Outbreaks Week, October 28th, 2003
The collaboration and license agreement covers Biota's second-generation influenza compounds (Flunet) and a comparable and competitive Sankyo compound (R118958) that is already in human clinical trials. The agreement consummates a letter of intent that was executed between the companies on May 23, 2003.
The second-generation compounds are longer acting than any currently available flu treatments. While the existing drugs need to be administered twice per day, the new drugs may only need to be...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week